JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study

BACKGROUND: The efficacy, safety, and pharmacokinetics of the combination of three direct-acting antiviral (DAA) agents (adafosbuvir [also known as AL-335], odalasvir, and simeprevir) were investigated in DAA treatment-naïve Japanese patients with genotype (GT)1 or GT2 chronic hepatitis C virus (HCV...

Descripción completa

Detalles Bibliográficos
Autores principales: Takehara, Tetsuo, Chayama, Kazuaki, Kurosaki, Masayuki, Yatsuhashi, Hiroshi, Tanaka, Yasuhito, Hiramatsu, Naoki, Sakamoto, Naoya, Asahina, Yasuhiro, Nozaki, Akito, Nakano, Toshikazu, Hagiwara, Yosuke, Shimizu, Hiroko, Yoshida, Hiroki, Huang, Yuhan, Biermer, Michael, Vijgen, Leen, Hayashi, Norio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Original Article—Liver, Pancreas, and Biliary Tract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242285/
https://www.ncbi.nlm.nih.gov/pubmed/32065330
http://dx.doi.org/10.1007/s00535-020-01672-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242285/
https://www.ncbi.nlm.nih.gov/pubmed/32065330
http://dx.doi.org/10.1007/s00535-020-01672-0

Ejemplares similares